This week, two clinical trials that are moving to the next phase were announced involving potential treatments for people with ALS.
On October 30, Neuraltus Pharmaceuticals announced that it is planning a Phase III clinical program to continue to study of its drug, NP001, in people with ALS. According to the company, its Phase II clinical study demonstrated positive trends in slowing the rate of disease progression, and NP001 was found to be safe and well-tolerated. The data will be presented at the 23rd International Symposium on ALS/MND in Chicago this December.
The Phase III study is expected to begin in the second half of 2013. The ALS Association is in dialogue with the investigators who were involved in the Phase II study and will provide additional information as it becomes available. Neuraltus has set up a toll-free number, which is available through December 31, 2012, for questions about the study: 1-888-347-7799.
On October 29, Cytokinetics, Incorporated, announced a Phase IIb clinical trial to continue studying it drug, tirasemtiv, formerly known as CK-2017357, in people with ALS. It has opened BENEFIT-ALS (Blinded Evaluation of Neuromusclar Effects and Functional Improvement with Tirasemtiv in ALS), formerly known as CY 4026, to enrollment.